metylfenidat actavis forðatafla 27 mg
actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 27 mg
metylfenidat actavis forðatafla 36 mg
actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 36 mg
metylfenidat actavis forðatafla 54 mg
actavis group ptc ehf. - methylphenidatum hýdróklóríð - forðatafla - 54 mg
ritalin tafla 10 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - tafla - 10 mg
ritalin uno hart hylki með breyttan losunarhraða 10 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 10 mg
ritalin uno hart hylki með breyttan losunarhraða 20 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 20 mg
ritalin uno hart hylki með breyttan losunarhraða 30 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 30 mg
ritalin uno hart hylki með breyttan losunarhraða 40 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 40 mg
ritalin uno hart hylki með breyttan losunarhraða 60 mg
infectopharm arzneimittel und consilium gmbh* - methylphenidatum hýdróklóríð - hart hylki með breyttan losunarhraða - 60 mg
tyruko
sandoz gmbh - natalízúmab - multiple sclerosis, relapsing-remitting; multiple sclerosis - Ónæmisbælandi lyf - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 og 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.